Alongside appreciating the nature of growth investing from a risk perspective, Ian Battersby argues it is critical advisers obtain comfort from providers over both deal-flow quality and deployment capability
So the dust is settling in the aftermath of the Patient Capital Review and Enterprise Investment Scheme (EIS) season is in full swing. The future is all about growth companies. It now seems to be accepted...
Industry compensation scheme refuses to cover it
No-deal Brexit will cause 'a tremendous shock on the UK economy'
‘If our people are the best they can be, then so is our service’
Asset managers must make changes
Follows exit of Hamish Purdey